Summary:
- This article discusses the enrollment of the first patient in a clinical trial for a new cancer treatment called LBL-024, developed by Leads Biolabs.
- LBL-024 is designed to target esophageal squamous cell carcinoma (ESCC), a type of cancer that has a high incidence in China.
- The treatment works by targeting both the PD-L1 and 4-1BB pathways, which the article suggests may provide superior survival benefits for patients compared to existing treatments.